By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Hikma Pharmaceuticals 

13 Hanover Square

London    W1S 1HL  United Kingdom
Phone: 44-0-20-7399-2760 Fax: 44-0-20-7399-2761



Company News
Vectura (VEC.L) Release: Hikma (HIK.L) Interim Results Statement On Its ANDA For Generic Advair Diskus (VR315) 8/17/2017 7:32:22 AM
Hikma (HIK.L) Announces Expanded Licensing Agreement With Takeda (TKPYY) For New Products In The Middle East And North Africa 8/17/2017 6:22:57 AM
Jazz Pharma (JAZZ) Reaches Settlement With Hikma (HIK.L) Related To Xyrem Patent Litigation 4/6/2017 6:48:03 AM
Hikma (HIK.L) Halves Cash Offer for Boehringer Ingelheim's Roxane, Will Pay $575 Million Less 2/10/2016 5:46:32 AM
Hikma (HIK.L) Receives FDA Approval For Neostigmine Methylsulfate Injection 1/4/2016 10:57:25 AM
Xellia Expands U.S. Production With Acquisition Of Manufacturing Plant From Hikma (HIK.L) 11/25/2015 10:22:30 AM
Hikma (HIK.L) Announces Successful Resolution To FDA Warning Letter At Its Portugal Facility 11/18/2015 10:16:17 AM
Hikma (HIK.L) Launches Phentolamine Mesylate Injection In The U.S. 11/5/2015 9:48:49 AM
Hikma (HIK.L) Signs Exclusive Licensing, Distribution And Supply Agreement With Basilea Pharmaceutica International Ltd. For Zevtera 10/15/2015 11:14:08 AM
Hikma (HIK.L) Interim Results 8/19/2015 9:42:45 AM